Get the Stockscreener App
0.3281
3.02%
-0.0102
After Hours:
.32
-0.0081
-2.47%
Profusa Inc stock is traded at $0.3281, with a volume of 1.14M.
It is down -3.02% in the last 24 hours and up +23.81% over the past month.
Profusa Inc is a digital health technology company based in Emeryville, CA, that has developed a real-time, consumer-friendly platform that is designed to measure an individual's biochemistry, be easy to use, be cost-effective, and provide the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
See More
Previous Close:
$0.3383
Open:
$0.345
24h Volume:
1.14M
Relative Volume:
0.12
Market Cap:
$11.84M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.94%
1M Performance:
+23.81%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.3149
$0.3495
1-Week Range:
$0.3149
$0.39
52-Week Range:
$0.265
$2.22
Profusa Inc Stock (PFSA) Company Profile
Name
Profusa Inc
Sector
Industry
Phone
212-494-9022
Address
207 WEST 25TH ST, 9TH FLOOR, NEW YORK
Compare PFSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFSA
Profusa Inc
|
0.3281 | 13.82M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Profusa Inc Stock (PFSA) Latest News
Profusa files prospectus relates to resale of up to 42.6 mln shares - MarketScreener
Profusa injects additional USD 1M into digital treasury assets - Medical Buyer
Profusa Invests $1 Million in Digital Treasury Assets - TipRanks
Profusa makes second $1 million bitcoin investment to hedge risks By Investing.com - Investing.com Nigeria
Profusa invests additional $1 million in digital treasury assets - MSN
Profusa, Inc. announced that it has received $1 million in funding - MarketScreener
Profusa invests additional $1 million in bitcoin treasury assets By Investing.com - Investing.com
Profusa, Inc. Announces $1 Million Investment in Digital Treasury Assets to Support Biochemical Monitoring Technology - Quiver Quantitative
Second $1M Investment: Profusa Expands Bitcoin Digital Treasury Strategy; Ascent Funds $2M Tranche - Stock Titan
French vascular surgeon adopts Profusa’s oxygen monitoring tech By Investing.com - Investing.com Nigeria
French vascular surgeon adopts Profusa’s oxygen monitoring tech - Investing.com India
Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base - The Manila Times
8% of French CLTI Cases: Profusa's Lumee Technology Gains Major Adoption from Leading Surgeon Network - Stock Titan
Profusa’s Risky Vision for High-Tech Medical Sensors - Finimize
Profusa Restructures Securities Agreement for Flexibility - MSN
Profusa Faces Nasdaq Listing Compliance Challenges - MSN
Profusa receives Nasdaq notices for minimum value and bid price compliance - Investing.com
Profusa Approves $100 Million Equity Line of Credit - MSN
This Penny Stock Is Surging on an Nvidia Boost. Should You Buy Shares Now or Stay Far Away? - Barchart.com
Profusa (PFSA) Stock: Soars 76% on NVIDIA-Powered AI Breakthrough in Biochemistry Monitoring - parameter.io
Report Highlights Growth in AI Biomarker Monitoring as Industry Giant's GPUs Power Next-Gen Platform - Yahoo Finance
Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring - GlobeNewswire
Profusa, Inc. Adopts NVIDIA -Powered Technology to Build Ai-Driven Insight Portal for Continuous Biomarker Monitoring - MarketScreener
Profusa shareholders approve $100 million equity line of credit with Ascent Partners By Investing.com - Investing.com South Africa
Profusa shareholders approve $100 million equity line of credit with Ascent Partners - Investing.com Australia
Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base - GlobeNewswire
300+ CLTI Patients Annually: Profusa's Oxygen Monitoring Tech Enters Major Belgian Hospital - Stock Titan
Profusa's Strategic Position in Digital Health Innovation - AInvest
Profusa to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
Digital Health Pioneer Profusa to Showcase Continuous Biochemistry Monitoring Tech at Major Conference - Stock Titan
Profusa announces commercial and clinical collaboration with head of angiography, Medical University of Graz, Austria - MarketScreener
Profusa Announces Commercial and Clinical Collaboration - GlobeNewswire
Leading Vascular Center Adopts Profusa's Real-Time Oxygen Monitoring Tech for 1,500 Annual Procedures - Stock Titan
Profusa amends purchase agreement and note terms for convertible debt tranches - Investing.com Australia
Profusa Restructures Securities Agreement for Enhanced Flexibility - AInvest
Profusa Inc Stock (PFSA) Financials Data
There is no financial data for Profusa Inc (PFSA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):